UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

Journal of clinical oncology, 1998-02, Vol.16 (2), p.453-461

1998

Volltextzugriff (PDF)

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer

Clinical cancer research, 1995-12, Vol.1 (12), p.1511-1515

1995

Volltextzugriff (PDF)

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

Annals of oncology, 1996-01, Vol.7 (1), p.99-102

1996

Volltextzugriff (PDF)

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer

Cancer, 1995-04, Vol.75 (8), p.2132-2138

1995

Volltextzugriff (PDF)

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer

Cancer research (Chicago, Ill.), 1993-01, Vol.53 (2), p.266-270

1993

Volltextzugriff (PDF)

Letrozole: updated duration of response

Journal of clinical oncology, 1999-12, Vol.17 (12), p.3856-3860

1999

Volltextzugriff (PDF)

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women

The journal of clinical endocrinology and metabolism, 1993-08, Vol.77 (2), p.324-331

1993

Volltextzugriff (PDF)

Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects

The journal of clinical endocrinology and metabolism, 1993-08, Vol.77 (2), p.319-323

1993

Volltextzugriff (PDF)

CENTRAL BLOOD PRESSURE AND AUGMENTATION INDEX DECREASE ARE DEPENDENT ON AORTIC PULSE WAVE VELOCITY IMPROVEMENT: THE EXPLOR STUDY: PP.10.406

Journal of hypertension, 2010-06, Vol.28, p.e171

2010

Volltextzugriff (PDF)

Effect of omalizumab in health care workers with occupational latex allergy

Journal of allergy and clinical immunology, 2004-02, Vol.113 (2), p.360-361

2004

Volltextzugriff (PDF)

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer

British journal of cancer, 1996-02, Vol.73 (4), p.539-542

1996

Volltextzugriff (PDF)

The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects

The journal of clinical endocrinology and metabolism, 1992-03, Vol.74 (3), p.571-576

1992

Volltextzugriff (PDF)

Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male

Journal of steroid biochemistry and molecular biology, 1992-03, Vol.41 (3), p.437-443

1992

Volltextzugriff (PDF)

Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer

European journal of cancer (1990), 1994, Vol.30A (10), p.1453-1458

1994

Volltextzugriff (PDF)

Letrozole: which dose to be used?

Journal of clinical oncology, 2000-04, Vol.18 (8), p.1802-1803

2000

Volltextzugriff (PDF)

Clinical use of aromatase inhibitors in the treatment of advanced breast cancer

Journal of steroid biochemistry and molecular biology, 1997-04, Vol.61 (3), p.241-245

1997

Volltextzugriff (PDF)

Letrozole (CGS 20267), A New Oral Aromatase Inhibitor for the Treatment of Advanced Breast Cancer in Postmenopausal Patients

Acta oncologica, 1996, Vol.35 (S5), p.15-18

1996

Volltextzugriff (PDF)

Influence of age, previous health status, and severity of acute illness on outcome from intensive care

Critical care medicine, 1982-09, Vol.10 (9), p.575-577

1982

Volltextzugriff (PDF)

New developments in the hormonal treatment of breast cancer in postmenopausal women

Bulletin du cancer, 1999-10, Vol.86 (10), p.815

1999

Volltextzugriff (PDF)

COMPARATIVE BIOAVAILABILITY OF LETROZOLE UNDER FED AND FASTING CONDITIONS IN 12 HEALTHY SUBJECTS AFTER A 2·5 MG SINGLE ORAL ADMINISTRATION

Biopharmaceutics & drug disposition, 1997-08, Vol.18 (6), p.489-497

1997

Volltextzugriff (PDF)

Pirprofen-induced fulminant hepatitis

Gastroenterology (New York, N.Y. 1943), 1985-07, Vol.89 (1), p.210-213

1985

Volltextzugriff (PDF)

The role of iatrogenic disease in admissions to intensive care

JAMA : the journal of the American Medical Association, 1980-12, Vol.244 (23), p.2617

1980

Volltextzugriff (PDF)

Influence of Caloric Intake on the Respiratory Mode during Mandatory Minute Volume Ventilation

Chest, 1985-01, Vol.87 (1), p.67-72

1985

Volltextzugriff (PDF)

The role of drug-induced illness in admissions to an intensive care unit

Intensive care medicine, 1986, Vol.12 (1), p.43-46

1986

Volltextzugriff (PDF)

Decreased plasma epinephrine concentrations after glucose ingestion in humans

Metabolism, clinical and experimental, 1984-01, Vol.33 (2), p.101-103

1984

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(53)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer

Letrozole: updated duration of response

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women

Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects

CENTRAL BLOOD PRESSURE AND AUGMENTATION INDEX DECREASE ARE DEPENDENT ON AORTIC PULSE WAVE VELOCITY IMPROVEMENT: THE EXPLOR STUDY: PP.10.406

Effect of omalizumab in health care workers with occupational latex allergy

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer

The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects

Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male

Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer

Letrozole: which dose to be used?

Clinical use of aromatase inhibitors in the treatment of advanced breast cancer

Letrozole (CGS 20267), A New Oral Aromatase Inhibitor for the Treatment of Advanced Breast Cancer in Postmenopausal Patients

Influence of age, previous health status, and severity of acute illness on outcome from intensive care

New developments in the hormonal treatment of breast cancer in postmenopausal women

COMPARATIVE BIOAVAILABILITY OF LETROZOLE UNDER FED AND FASTING CONDITIONS IN 12 HEALTHY SUBJECTS AFTER A 2·5 MG SINGLE ORAL ADMINISTRATION

Pirprofen-induced fulminant hepatitis

The role of iatrogenic disease in admissions to intensive care

Influence of Caloric Intake on the Respiratory Mode during Mandatory Minute Volume Ventilation

The role of drug-induced illness in admissions to an intensive care unit

Decreased plasma epinephrine concentrations after glucose ingestion in humans

Suchergebnisse filtern